POTS & DYSAUTONOMIA

POTS & Dysautonomia Genetic Testing — postural orthostatic tachycardia syndrome is increasingly understood as part of a connective tissue–mast cell–autonomic triad, where genetic evaluation reveals the underlying biology driving treatment selection.

Whole genome sequencing evaluates connective tissue genes (COL5A1, TNXB, COL3A1), ion channel variants (SCN9A, SCN10A), mast cell genes (TPSAB1/hereditary alpha tryptasemia), and autonomic pathway genes — providing the genetic architecture underlying POTS and dysautonomia.

COL5A1
TNXB
COL3A1
SCN9A
SCN10A
TPSAB1
KIT

About this condition

POTS & Dysautonomia — Genetic Testing

Postural orthostatic tachycardia syndrome (POTS) affects an estimated 1-3 million Americans, characterized by excessive heart rate increase upon standing (≥30 bpm or ≥120 bpm within 10 minutes) with orthostatic symptoms including lightheadedness, palpitations, presyncope, exercise intolerance, brain fog, and fatigue. POTS is not a single disease but a final common pathway of multiple underlying conditions — including connective tissue disorders, mast cell activation, small fiber neuropathy, autoimmune autonomic neuropathy, and primary autonomic dysfunction.

The EDS-POTS-MCAS triad (hypermobile Ehlers-Danlos syndrome, POTS, and mast cell activation syndrome) is increasingly recognized as a clinical entity. Up to 50% of hypermobile EDS patients have POTS, and up to 66% have mast cell activation features. Connective tissue laxity in blood vessel walls may allow excessive venous pooling, triggering compensatory tachycardia. Genetic variants in connective tissue genes (COL5A1, TNXB — tenascin-X deficiency, FLNB, COL3A1) and mast cell genes (TPSAB1 — hereditary alpha tryptasemia, KIT) contribute to this triad. SCN9A and SCN10A sodium channel variants affect small fiber nerve function and autonomic reflexes.

While POTS has traditionally been considered a functional or poorly understood condition, genetic evaluation is transforming it into a biologically characterized syndrome. Identification of connective tissue variants directs patients toward joint protection strategies, compression garments (addressing the vascular mechanism), and appropriate physical therapy approaches. Hereditary alpha tryptasemia (HαT, TPSAB1 duplication) identification guides mast cell-targeted therapy (antihistamines, mast cell stabilizers). SCN9A variants may guide sodium channel modulator therapy. This genetic subtyping of POTS represents an emerging precision medicine approach.

The EDS-POTS-MCAS triad is one of the most underdiagnosed genetic conditions in medicine. Patients see an average of 7 specialists before diagnosis. Genetic evaluation of connective tissue and mast cell genes can unify these seemingly unrelated symptoms.

Gene locus: COL5A1 (9q34.3), TNXB (6p21.33), COL3A1 (2q32.2), SCN9A (2q24.3), SCN10A (3p22.2), TPSAB1 (16p13.3), KIT (4q12)

POTS patients average 7 specialist visits before diagnosis. Genetic evaluation reveals the biological mechanism — EDS, mast cell activation, or autonomic neuropathy — directing treatment to the underlying cause rather than treating symptoms empirically.

Hereditary alpha tryptasemia (HαT) is found in ~5% of the general population — and is significantly enriched in POTS/MCAS patients

TPSAB1 duplication (hereditary alpha tryptasemia) causes elevated baseline serum tryptase and is associated with dysautonomia, flushing, GI dysmotility, and systemic reactions. HαT is significantly enriched in POTS and MCAS cohorts. Identification of HαT directs treatment toward mast cell stabilization (cromolyn, ketotifen) and antihistamine therapy — an approach that may not be considered without the genetic finding. WGS can evaluate TPSAB1 copy number alongside connective tissue gene analysis.

Connective tissue variant identification explains WHY compression garments work — and directs the rest of the POTS treatment plan

Identifying connective tissue gene variants (COL5A1, TNXB, FLNB) in a POTS patient provides the structural explanation for excessive venous pooling upon standing. This understanding guides treatment: compression garments (addressing vascular laxity), increased salt/fluid intake (expanding blood volume), targeted exercise (reconditioning deconditioned vasculature), and physical therapy focused on proprioception and joint protection. Without the connective tissue diagnosis, POTS treatment remains empirical rather than mechanism-targeted.

POTS & Dysautonomia Genetic Testing — postural orthostatic tachycardia syndrome is increasingly understood as part of a connective tissue–mast cell–autonomic triad, where genetic evaluation reveals the underlying biology driving treatment selection.

POTS & Dysautonomia — Genetic Testing

POTS patients average 7 specialist visits before diagnosis. Genetic evaluation reveals the biological mechanism — EDS, mast cell activation, or autonomic neuropathy — directing treatment to the underlying cause rather than treating symptoms empirically.

Hereditary alpha tryptasemia (HαT) is found in ~5% of the general population — and is significantly enriched in POTS/MCAS patients

Connective tissue variant identification explains WHY compression garments work — and directs the rest of the POTS treatment plan

Others in Rare Diseases

One test. A lifetime of answers.